BioAge Labs, Inc. (BIOA) Stock

About BioAge Labs, Inc.

BioAge Labs, Inc. is led by CEO Kristen Fortney, publicly traded since 2024.

BioAge Labs, Inc. (BIOA) stock trades at $5.10 with a market capitalization of $192.01M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.73, reflecting a net loss over the last twelve months, price-to-book of 0.78, price-to-sales of 23.63. Over the past 52 weeks the stock has ranged between $3.67 and $25.96, and currently trades 80.4% below its 52-week high.

On profitability, BioAge Labs, Inc. generates a return on equity (ROE) of -28.99% (negative, reflecting a net loss), return on capital employed of -28.14%, an operating margin of -9.86%, a net profit margin of -912.25%.

BioAge Labs, Inc. by the numbers, 2022–2025

Between 2022 and 2025 BioAge Labs, Inc. reported revenue of $0 rising to $9.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-81.0M.

The most recent net margin is -912.25%. On a trailing twelve-month basis to Jun '26, revenue is $10.0M and net profit $-94.0M.

Borrowings rose from $2.0M to $6.0M, cash from operations was $-82.0M in the latest year, positive in 0 of the last 4.

Return on equity has averaged 5.2% over five years, and was -29.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, 325.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BioAge Labs, Inc. (BIOA) — frequently asked questions